• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAA 5.56% 17.0¢

PHARMAUST LIMITED - Announcements

PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for... PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The Company’s segments include Corporate and Research. The Company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The Company is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. It is focused on starting Phase II/III clinical study of MPL. It has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. It is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.More

Announcements


PAA Appendix 2A & s708 notice (exercise of options)07/07/20 download Created with Sketch. 410.64KB
PAA PharmAust Shareholder UpdatePRICE SENSITIVE24/06/20 download Created with Sketch. 955.83KB
PAA Reinstatement to Official QuotationPRICE SENSITIVE18/06/20 download Created with Sketch. 71.7KB
PAA Confirmation of Preliminary COVID-19 ResultsPRICE SENSITIVE18/06/20 download Created with Sketch. 868.39KB
PAA Voluntary SuspensionPRICE SENSITIVE15/06/20 download Created with Sketch. 183.09KB
PAA Trading HaltPRICE SENSITIVE11/06/20 download Created with Sketch. 538.13KB
PAA Virtual Investor Briefing PresentationPRICE SENSITIVE10/06/20 download Created with Sketch. 2.15MB
PAA Virtual Investor Briefing05/06/20 download Created with Sketch. 407.76KB
PAA Reinstatement to Official QuotationPRICE SENSITIVE04/06/20 download Created with Sketch. 212.66KB
PAA Preliminary Positive Results for the Treatment of SARS-CoV-2PRICE SENSITIVE04/06/20 download Created with Sketch. 611.92KB
PAA Suspension from Official QuotationPRICE SENSITIVE02/06/20 download Created with Sketch. 345.13KB
PAA Trading HaltPRICE SENSITIVE29/05/20 download Created with Sketch. 216.92KB
PAA Pause in TradingPRICE SENSITIVE29/05/20 download Created with Sketch. 116.22KB
PAA Monepantel Trial Achieves Successful Anti-Cancer OutcomePRICE SENSITIVE12/05/20 download Created with Sketch. 414.2KB
PAA Trading HaltPRICE SENSITIVE08/05/20 download Created with Sketch. 204.4KB
PAA Appendix 3G30/04/20 download Created with Sketch. 307.12KB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE20/04/20 download Created with Sketch. 402.02KB
PAA PharmAust to Evaluate Monepantel on COVID-19PRICE SENSITIVE17/04/20 download Created with Sketch. 201.81KB
PAA Expiry of Options31/03/20 download Created with Sketch. 143.8KB
PAA Phase II Dog Cancer Trial Update31/03/20 download Created with Sketch. 164.81KB
PAA Brisbane Animal Hospital Joins Phase II Dog Cancer TrialPRICE SENSITIVE03/03/20 download Created with Sketch. 187.06KB
PAA Appendix 4D & Half Year ReportPRICE SENSITIVE28/02/20 download Created with Sketch. 611.34KB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE28/01/20 download Created with Sketch. 350.98KB
PAA PharmAust Receives $700k R&D Tax Incentive RefundPRICE SENSITIVE14/01/20 download Created with Sketch. 158.09KB
PAA Epichem Awarded One-Year Contract Extension from DNDiPRICE SENSITIVE08/01/20 download Created with Sketch. 190.71KB
PAA Epichem client gives notice to end contract in February 2020PRICE SENSITIVE07/01/20 download Created with Sketch. 170.1KB
PAA Expanded Site Recruitment for Phase II MPL Dog Cancer TrialPRICE SENSITIVE11/12/19 download Created with Sketch. 200.45KB
PAA Appendix 3B - exercise of options09/12/19 download Created with Sketch. 306.49KB
PAA Presentation - Pitt Street Research Life Sciences ConferencePRICE SENSITIVE28/11/19 download Created with Sketch. 3.66MB
PAA Appendix 3B - exercise of options21/11/19 download Created with Sketch. 306.36KB
PAA Appendix 3B - exercise of options08/11/19 download Created with Sketch. 306.39KB
PAA Progress in Recruitment for Phase II Trial in DogsPRICE SENSITIVE04/11/19 download Created with Sketch. 202.45KB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE01/11/19 download Created with Sketch. 261.26KB
PAA Results of Annual General Meeting25/10/19 download Created with Sketch. 211.52KB
PAA AGM PresentationPRICE SENSITIVE25/10/19 download Created with Sketch. 3.58MB
PAA Epichem new CEO and Board additionsPRICE SENSITIVE14/10/19 download Created with Sketch. 242.4KB
PAA Appendix 3B & s708 NoticePRICE SENSITIVE10/10/19 download Created with Sketch. 413.53KB
PAA PharmAust Receives Pre-Approval for R&D Tax RebatesPRICE SENSITIVE07/10/19 download Created with Sketch. 165.83KB
PAA Epichem Export Business Receives Important WA State AwardsPRICE SENSITIVE04/10/19 download Created with Sketch. 159.63KB
PAA PharmAust Raises $2.4m in PlacementPRICE SENSITIVE03/10/19 download Created with Sketch. 156.44KB
PAA Trading HaltPRICE SENSITIVE01/10/19 download Created with Sketch. 203.13KB
PAA Appendix 3B - exercise of options26/09/19 download Created with Sketch. 308.02KB
PAA Notice of Annual General Meeting/Proxy Form24/09/19 download Created with Sketch. 326.13KB
PAA Appendix 4G & Corporate Governance Statement19/09/19 download Created with Sketch. 400.35KB
PAA Annual Report19/09/19 download Created with Sketch. 806.55KB
PAA Appendix 3B - exercise of options17/09/19 download Created with Sketch. 308.03KB
PAA Agreement with Uni of Melbourne U-Vet for Phase II Dog TrialPRICE SENSITIVE10/09/19 download Created with Sketch. 186.95KB
PAA Phase II Dog Cancer Trial CommencesPRICE SENSITIVE09/09/19 download Created with Sketch. 176.58KB
PAA Investor Roadshow Presentation - September 2019PRICE SENSITIVE09/09/19 download Created with Sketch. 1.03MB
PAA Preliminary Final ReportPRICE SENSITIVE30/08/19 download Created with Sketch. 323.11KB
PAA Appendix 3B & s708 notice28/08/19 download Created with Sketch. 410.3KB
PAA Receipt of GMP Grade Tablets for Phase II TrialsPRICE SENSITIVE26/08/19 download Created with Sketch. 174.14KB
PAA Change of Director's Interest Notice16/08/19 download Created with Sketch. 183.51KB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE31/07/19 download Created with Sketch. 261.23KB
PAA Appendix 3B & s708 notice26/07/19 download Created with Sketch. 409.96KB
PAA Investor Presentation25/07/19 download Created with Sketch. 1.4MB
PAA Response to ASX Price and Volume QueryPRICE SENSITIVE23/07/19 download Created with Sketch. 252.39KB
PAA Pause In TradingPRICE SENSITIVE23/07/19 download Created with Sketch. 116.1KB
PAA Change in substantial holding23/07/19 download Created with Sketch. 173.95KB
PAA PharmAust receives ethics approval to begin Phase II TrialPRICE SENSITIVE15/07/19 download Created with Sketch. 145.18KB
PAA Epichem Final Loan Repayment Milestone for New LaboratoryPRICE SENSITIVE02/07/19 download Created with Sketch. 144.77KB
PAA PharmAust Commences GMP Tablet Manufacture for Phase 2 TrialPRICE SENSITIVE04/06/19 download Created with Sketch. 148.74KB
PAA Receipt of 25kg of GMP-Grade Monepantel from ElancoPRICE SENSITIVE08/05/19 download Created with Sketch. 138.52KB
PAA Phase I Canine Repeat Dose MPL Demonstrates High PerformancePRICE SENSITIVE06/05/19 download Created with Sketch. 144.23KB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE01/05/19 download Created with Sketch. 262.98KB
PAA PharmAust Receives $672,250 R&D Tax Incentive RefundPRICE SENSITIVE30/04/19 download Created with Sketch. 141.27KB
PAA Appendix 3B24/04/19 download Created with Sketch. 308.42KB
PAA Shortfall Placement OversubscribedPRICE SENSITIVE11/04/19 download Created with Sketch. 154.7KB
PAA Change of Director's Interest Notice x 429/03/19 download Created with Sketch. 248.28KB
PAA Phase I Monepantel Tablets Demonstrate High SafetyPRICE SENSITIVE28/03/19 download Created with Sketch. 146.46KB
PAA PharmAust Raises $1.3m in Rights IssuePRICE SENSITIVE22/03/19 download Created with Sketch. 158.69KB
PAA MPL Tablets Demonstrate Positive Performance in Phase 1PRICE SENSITIVE14/03/19 download Created with Sketch. 170.87KB
PAA PharmAust Rights Issue Reaches Minimum SubscriptionPRICE SENSITIVE12/03/19 download Created with Sketch. 152.62KB
PAA PharmAust Intellectual Property Update05/03/19 download Created with Sketch. 201.6KB
PAA Appendix 4D & Financial ReportPRICE SENSITIVE01/03/19 download Created with Sketch. 1.03MB
PAA Offer Document - Rights IssuePRICE SENSITIVE26/02/19 download Created with Sketch. 266.27KB
PAA Phase I Dog Trial with New Monepantel Tablets CommencesPRICE SENSITIVE20/02/19 download Created with Sketch. 175.38KB
PAA Letter to Shareholders19/02/19 download Created with Sketch. 200.33KB
PAA Epichem Awarded One-Year Contract Extension from DNDiPRICE SENSITIVE18/02/19 download Created with Sketch. 126.56KB
PAA Letter to Optionholders18/02/19 download Created with Sketch. 207.9KB
PAA Section 708AA Notice18/02/19 download Created with Sketch. 199.47KB
PAA Appendix 3B18/02/19 download Created with Sketch. 444.71KB
PAA Non-Renounceable Rights OfferPRICE SENSITIVE18/02/19 download Created with Sketch. 194.56KB
PAA Appendix 3B - Amendment14/02/19 download Created with Sketch. 499.21KB
PAA PAA Completes Successful Taste Mask Testing of New TabletPRICE SENSITIVE11/02/19 download Created with Sketch. 187.81KB
PAA Section 708 Notice07/02/19 download Created with Sketch. 129.49KB
PAA Appendix 3B07/02/19 download Created with Sketch. 430.58KB
PAA PharmAust Signs Agreement for US Phase I Trials in DogsPRICE SENSITIVE07/02/19 download Created with Sketch. 178.54KB
PAA PharmAust Completes Scaled Manufacture of Monepantel TabletsPRICE SENSITIVE07/02/19 download Created with Sketch. 179.84KB
PAA PharmAust Appendix 4C and Shareholders' UpdatePRICE SENSITIVE31/01/19 download Created with Sketch. 347.78KB
PAA PharmAust and Elanco Execute Data Sharing AgreementPRICE SENSITIVE29/01/19 download Created with Sketch. 144.22KB
PAA Optimisation of Monepantel UptakePRICE SENSITIVE21/01/19 download Created with Sketch. 176.98KB
PAA Monepantel Principal Metabolite Shows Anti-Cancer ActivityPRICE SENSITIVE14/01/19 download Created with Sketch. 177.85KB
PAA PharmAust Develops Method for MPL/Analogue ManufacturePRICE SENSITIVE03/12/18 download Created with Sketch. 165.01KB
PAA GMP Tablet Manufacture Commences for Canine Clinical TrialsPRICE SENSITIVE13/11/18 download Created with Sketch. 161.32KB
PAA Results of Annual General Meeting09/11/18 download Created with Sketch. 133.14KB
PAA AGM Presentation09/11/18 download Created with Sketch. 1.17MB
PAA Appendix 4C & Company Update - Sep 2018PRICE SENSITIVE01/11/18 download Created with Sketch. 348.47KB
PAA PharmAust Develops GMP Method for Monepantel AnaloguesPRICE SENSITIVE29/10/18 download Created with Sketch. 160.25KB
PAA PharmAust Progresses Monepantel Tablet Program for CancerPRICE SENSITIVE15/10/18 download Created with Sketch. 153.6KB
PAA Appendix 2A & s708 notice (exercise of options)
07/07/20 download Created with Sketch. 410.64KB
PAA PharmAust Shareholder Update
24/06/20PRICE SENSITIVE download Created with Sketch. 955.83KB
PAA Reinstatement to Official Quotation
18/06/20PRICE SENSITIVE download Created with Sketch. 71.7KB
PAA Confirmation of Preliminary COVID-19 Results
18/06/20PRICE SENSITIVE download Created with Sketch. 868.39KB
PAA Voluntary Suspension
15/06/20PRICE SENSITIVE download Created with Sketch. 183.09KB
PAA Trading Halt
11/06/20PRICE SENSITIVE download Created with Sketch. 538.13KB
PAA Virtual Investor Briefing Presentation
10/06/20PRICE SENSITIVE download Created with Sketch. 2.15MB
PAA Virtual Investor Briefing
05/06/20 download Created with Sketch. 407.76KB
PAA Reinstatement to Official Quotation
04/06/20PRICE SENSITIVE download Created with Sketch. 212.66KB
PAA Preliminary Positive Results for the Treatment of SARS-CoV-2
04/06/20PRICE SENSITIVE download Created with Sketch. 611.92KB
PAA Suspension from Official Quotation
02/06/20PRICE SENSITIVE download Created with Sketch. 345.13KB
PAA Trading Halt
29/05/20PRICE SENSITIVE download Created with Sketch. 216.92KB
PAA Pause in Trading
29/05/20PRICE SENSITIVE download Created with Sketch. 116.22KB
PAA Monepantel Trial Achieves Successful Anti-Cancer Outcome
12/05/20PRICE SENSITIVE download Created with Sketch. 414.2KB
PAA Trading Halt
08/05/20PRICE SENSITIVE download Created with Sketch. 204.4KB
PAA Appendix 3G
30/04/20 download Created with Sketch. 307.12KB
PAA Appendix 4C and Quarterly Update
20/04/20PRICE SENSITIVE download Created with Sketch. 402.02KB
PAA PharmAust to Evaluate Monepantel on COVID-19
17/04/20PRICE SENSITIVE download Created with Sketch. 201.81KB
PAA Expiry of Options
31/03/20 download Created with Sketch. 143.8KB
PAA Phase II Dog Cancer Trial Update
31/03/20 download Created with Sketch. 164.81KB
PAA Brisbane Animal Hospital Joins Phase II Dog Cancer Trial
03/03/20PRICE SENSITIVE download Created with Sketch. 187.06KB
PAA Appendix 4D & Half Year Report
28/02/20PRICE SENSITIVE download Created with Sketch. 611.34KB
PAA Appendix 4C and Quarterly Update
28/01/20PRICE SENSITIVE download Created with Sketch. 350.98KB
PAA PharmAust Receives $700k R&D Tax Incentive Refund
14/01/20PRICE SENSITIVE download Created with Sketch. 158.09KB
PAA Epichem Awarded One-Year Contract Extension from DNDi
08/01/20PRICE SENSITIVE download Created with Sketch. 190.71KB
PAA Epichem client gives notice to end contract in February 2020
07/01/20PRICE SENSITIVE download Created with Sketch. 170.1KB
PAA Expanded Site Recruitment for Phase II MPL Dog Cancer Trial
11/12/19PRICE SENSITIVE download Created with Sketch. 200.45KB
PAA Appendix 3B - exercise of options
09/12/19 download Created with Sketch. 306.49KB
PAA Presentation - Pitt Street Research Life Sciences Conference
28/11/19PRICE SENSITIVE download Created with Sketch. 3.66MB
PAA Appendix 3B - exercise of options
21/11/19 download Created with Sketch. 306.36KB
PAA Appendix 3B - exercise of options
08/11/19 download Created with Sketch. 306.39KB
PAA Progress in Recruitment for Phase II Trial in Dogs
04/11/19PRICE SENSITIVE download Created with Sketch. 202.45KB
PAA Appendix 4C and Quarterly Update
01/11/19PRICE SENSITIVE download Created with Sketch. 261.26KB
PAA Results of Annual General Meeting
25/10/19 download Created with Sketch. 211.52KB
PAA AGM Presentation
25/10/19PRICE SENSITIVE download Created with Sketch. 3.58MB
PAA Epichem new CEO and Board additions
14/10/19PRICE SENSITIVE download Created with Sketch. 242.4KB
PAA Appendix 3B & s708 Notice
10/10/19PRICE SENSITIVE download Created with Sketch. 413.53KB
PAA PharmAust Receives Pre-Approval for R&D Tax Rebates
07/10/19PRICE SENSITIVE download Created with Sketch. 165.83KB
PAA Epichem Export Business Receives Important WA State Awards
04/10/19PRICE SENSITIVE download Created with Sketch. 159.63KB
PAA PharmAust Raises $2.4m in Placement
03/10/19PRICE SENSITIVE download Created with Sketch. 156.44KB
PAA Trading Halt
01/10/19PRICE SENSITIVE download Created with Sketch. 203.13KB
PAA Appendix 3B - exercise of options
26/09/19 download Created with Sketch. 308.02KB
PAA Notice of Annual General Meeting/Proxy Form
24/09/19 download Created with Sketch. 326.13KB
PAA Appendix 4G & Corporate Governance Statement
19/09/19 download Created with Sketch. 400.35KB
PAA Annual Report
19/09/19 download Created with Sketch. 806.55KB
PAA Appendix 3B - exercise of options
17/09/19 download Created with Sketch. 308.03KB
PAA Agreement with Uni of Melbourne U-Vet for Phase II Dog Trial
10/09/19PRICE SENSITIVE download Created with Sketch. 186.95KB
PAA Phase II Dog Cancer Trial Commences
09/09/19PRICE SENSITIVE download Created with Sketch. 176.58KB
PAA Investor Roadshow Presentation - September 2019
09/09/19PRICE SENSITIVE download Created with Sketch. 1.03MB
PAA Preliminary Final Report
30/08/19PRICE SENSITIVE download Created with Sketch. 323.11KB
PAA Appendix 3B & s708 notice
28/08/19 download Created with Sketch. 410.3KB
PAA Receipt of GMP Grade Tablets for Phase II Trials
26/08/19PRICE SENSITIVE download Created with Sketch. 174.14KB
PAA Change of Director's Interest Notice
16/08/19 download Created with Sketch. 183.51KB
PAA Appendix 4C and Quarterly Update
31/07/19PRICE SENSITIVE download Created with Sketch. 261.23KB
PAA Appendix 3B & s708 notice
26/07/19 download Created with Sketch. 409.96KB
PAA Investor Presentation
25/07/19 download Created with Sketch. 1.4MB
PAA Response to ASX Price and Volume Query
23/07/19PRICE SENSITIVE download Created with Sketch. 252.39KB
PAA Pause In Trading
23/07/19PRICE SENSITIVE download Created with Sketch. 116.1KB
PAA Change in substantial holding
23/07/19 download Created with Sketch. 173.95KB
PAA PharmAust receives ethics approval to begin Phase II Trial
15/07/19PRICE SENSITIVE download Created with Sketch. 145.18KB
PAA Epichem Final Loan Repayment Milestone for New Laboratory
02/07/19PRICE SENSITIVE download Created with Sketch. 144.77KB
PAA PharmAust Commences GMP Tablet Manufacture for Phase 2 Trial
04/06/19PRICE SENSITIVE download Created with Sketch. 148.74KB
PAA Receipt of 25kg of GMP-Grade Monepantel from Elanco
08/05/19PRICE SENSITIVE download Created with Sketch. 138.52KB
PAA Phase I Canine Repeat Dose MPL Demonstrates High Performance
06/05/19PRICE SENSITIVE download Created with Sketch. 144.23KB
PAA Appendix 4C and Quarterly Update
01/05/19PRICE SENSITIVE download Created with Sketch. 262.98KB
PAA PharmAust Receives $672,250 R&D Tax Incentive Refund
30/04/19PRICE SENSITIVE download Created with Sketch. 141.27KB
PAA Appendix 3B
24/04/19 download Created with Sketch. 308.42KB
PAA Shortfall Placement Oversubscribed
11/04/19PRICE SENSITIVE download Created with Sketch. 154.7KB
PAA Change of Director's Interest Notice x 4
29/03/19 download Created with Sketch. 248.28KB
PAA Phase I Monepantel Tablets Demonstrate High Safety
28/03/19PRICE SENSITIVE download Created with Sketch. 146.46KB
PAA PharmAust Raises $1.3m in Rights Issue
22/03/19PRICE SENSITIVE download Created with Sketch. 158.69KB
PAA MPL Tablets Demonstrate Positive Performance in Phase 1
14/03/19PRICE SENSITIVE download Created with Sketch. 170.87KB
PAA PharmAust Rights Issue Reaches Minimum Subscription
12/03/19PRICE SENSITIVE download Created with Sketch. 152.62KB
PAA PharmAust Intellectual Property Update
05/03/19 download Created with Sketch. 201.6KB
PAA Appendix 4D & Financial Report
01/03/19PRICE SENSITIVE download Created with Sketch. 1.03MB
PAA Offer Document - Rights Issue
26/02/19PRICE SENSITIVE download Created with Sketch. 266.27KB
PAA Phase I Dog Trial with New Monepantel Tablets Commences
20/02/19PRICE SENSITIVE download Created with Sketch. 175.38KB
PAA Letter to Shareholders
19/02/19 download Created with Sketch. 200.33KB
PAA Epichem Awarded One-Year Contract Extension from DNDi
18/02/19PRICE SENSITIVE download Created with Sketch. 126.56KB
PAA Letter to Optionholders
18/02/19 download Created with Sketch. 207.9KB
PAA Section 708AA Notice
18/02/19 download Created with Sketch. 199.47KB
PAA Appendix 3B
18/02/19 download Created with Sketch. 444.71KB
PAA Non-Renounceable Rights Offer
18/02/19PRICE SENSITIVE download Created with Sketch. 194.56KB
PAA Appendix 3B - Amendment
14/02/19 download Created with Sketch. 499.21KB
PAA PAA Completes Successful Taste Mask Testing of New Tablet
11/02/19PRICE SENSITIVE download Created with Sketch. 187.81KB
PAA Section 708 Notice
07/02/19 download Created with Sketch. 129.49KB
PAA Appendix 3B
07/02/19 download Created with Sketch. 430.58KB
PAA PharmAust Signs Agreement for US Phase I Trials in Dogs
07/02/19PRICE SENSITIVE download Created with Sketch. 178.54KB
PAA PharmAust Completes Scaled Manufacture of Monepantel Tablets
07/02/19PRICE SENSITIVE download Created with Sketch. 179.84KB
PAA PharmAust Appendix 4C and Shareholders' Update
31/01/19PRICE SENSITIVE download Created with Sketch. 347.78KB
PAA PharmAust and Elanco Execute Data Sharing Agreement
29/01/19PRICE SENSITIVE download Created with Sketch. 144.22KB
PAA Optimisation of Monepantel Uptake
21/01/19PRICE SENSITIVE download Created with Sketch. 176.98KB
PAA Monepantel Principal Metabolite Shows Anti-Cancer Activity
14/01/19PRICE SENSITIVE download Created with Sketch. 177.85KB
PAA PharmAust Develops Method for MPL/Analogue Manufacture
03/12/18PRICE SENSITIVE download Created with Sketch. 165.01KB
PAA GMP Tablet Manufacture Commences for Canine Clinical Trials
13/11/18PRICE SENSITIVE download Created with Sketch. 161.32KB
PAA Results of Annual General Meeting
09/11/18 download Created with Sketch. 133.14KB
PAA AGM Presentation
09/11/18 download Created with Sketch. 1.17MB
PAA Appendix 4C & Company Update - Sep 2018
01/11/18PRICE SENSITIVE download Created with Sketch. 348.47KB
PAA PharmAust Develops GMP Method for Monepantel Analogues
29/10/18PRICE SENSITIVE download Created with Sketch. 160.25KB
PAA PharmAust Progresses Monepantel Tablet Program for Cancer
15/10/18PRICE SENSITIVE download Created with Sketch. 153.6KB
(20min delay)
Last
17.0¢
Change
-0.010(5.56%)
Mkt cap ! $67.30M
Open High Low Value Volume
17.5¢ 18.0¢ 16.3¢ $581.7K 3.408M

Buyers (Bids)

No. Vol. Price($)
4 502428 17.0¢
 

Sellers (Offers)

Price($) Vol. No.
17.5¢ 40529 1
View Market Depth
Last trade - 16.10pm 10/05/2024 (20 minute delay) ?
Last
17.5¢
  Change
-0.010 ( 3.15 %)
Open High Low Volume
17.5¢ 18.0¢ 16.0¢ 3492891
Last updated 15.59pm 10/05/2024 ?
PAA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.